HIV-Associated Hodgkins Lymphoma Prognosis and Therapy in the Era of cART.pdfVIP

Hindawi Publishing Corporation Advances in Hematology Volume 2012, Article ID 507257, 8 pages doi:10.1155/2012/507257 Review Article HIV-Associated Hodgkin’s Lymphoma: Prognosis and Therapy in the Era of cART Caron A. Jacobson1 and Jeremy S. Abramson2 1 Dana-Farber Cancer Institute, Boston, MA 02215, USA 2 Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA Correspondence should be addressed to Jeremy S. Abramson, jabramson@ Received 1 September 2011; Accepted 3 October 2011 Academic Editor: Heather Leitch Copyright © 2012 C. A. Jacobson and J. S. Abramson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) are at increased risk for developing Hodgkin’s lymphoma (HL), a risk that has not decreased despite the success of combination antiretroviral therapy (cART) in the modern era. HIV-associated HL (HIV-HL) differs from HL in non-HIV-infected patients in that it is nearly always associated with Epstein-Barr virus (EBV) and more often presents with high-risk features of advanced disease, systemic “B” symptoms, and extranodal involvement. Before the introduction of cART, patients with HIV-HL had lower response rates and worse outcomes than non-HIV-infected HL patients treated with conventional chemotherapy. The introduction of cART, however, has allowed for the delivery of full-dose and dose-intensive chemotherapy regimens with improved outcomes that approach those seen in non-HIV infected patients. Despite these significant advances, HIV-